Introduction
Deoxycorticosterone acetate (DOCA)-salt hypertensive challenge in mice resembles a condition of salt sensitivity, observed in some hypertensive patients and often leading to increased susceptibility to higher BP. 1 Although polydipsia and increased metabolic rate induced by DOCA-salt were considered as major culprits of the resulting hypertensive phenotype, a large body of researches focused the attention on the brain-mediated effects of DOCA-salt. 2, 3 It has been reported that the DOCA-salt model, optimal to reproduce low circulating levels of renin-angiotensin system (RAS) activity, 4 determines instead a concomitant elevation of brain RAS activity, [5] [6] [7] thus suggesting the existence of a brain-mediated overactivation of peripheral sympathetic tone. On a different note, it has been reported that DOCA-salt hypertension depends on the activation of adaptive immunity, in a way similar to that observed for angiotensin (AngII). 8 Thus, despite different etiology, AngII and DOCA-salt need mobilization of activated T cells directed towards target organs of hypertension, particularly to kidneys. 9 While lots of studies focused on immune mechanisms activated during DOCA-salt challenge and participating in the establishment of hypertensive disease, [9] [10] [11] [12] less is known about how the neurogenic effect of DOCA-salt connects to priming of immunity.
In a previous study, we found that the angiogenic placental growth factor (PlGF), belonging to vascular endothelial growth factors VEGFs family , mediates the neuroimmune coupling established in the spleen upon chronic AngII, playing a central role in the increase of BP. 13 It has been described that the activation of RAS activity in the brain exerted by AngII and acting through the AngII type 1 receptors 14 was similarly activated by DOCA-salt challenge. 7, 15 In particular, it has been shown that, despite lesions of the subfornical organ (SFO), a circumventricular organ acting as a sensory brain structure, were not able to prevent DOCA-salt effects on BP, 16 a highly selective deletion of AT 1a Rs in this area attenuated fluid intake and blunted the hypertensive response. 7 Overall, these data support the concept that the two hypertensive challenges, despite different in their nature, recruit a common pathway in the brain, which in turn recruit the hypertensive disease. In the most classical meaning, the activation of this pathway in the brain mediates the typical overactivation of the sympathetic nervous system (SNS) in peripheral districts typically controlling BP levels, like kidneys an vasculature. 17 More recently, we also showed that both AngII and DOCA-salt enhanced the sympathetic activity of the splenic nerve (SSNA) through a brain-vagus-splenic circuit. 18 However, it is still unknown whether the two hypertensive hits, with different peripheral mechanisms of action, share common neuroimmune mechanisms in the onset of hypertension. Here we tested the hypothesis that PlGF could mediate DOCA-salt hypertension by coupling nervous and immune systems in the spleen.
Methods

Mice
All the experimental procedures were performed according to European Communities guidelines and the Italian legislation on animal experimentation (Decreto L.vo 26/14). The protocol was approved by the Italian Ministry of Health and by our Institutional Committee. PlGF knock-out (KO), mice were backcrossed for 11 generations in C57Bl/6 J mice from the original strain in 50% 129 Sv/50% Swiss mice. 19 Wild-type (WT) mice with the same genetic background (C57Bl/6 J) were obtained from the KO colony and used as the appropriate control strain. Where indicated, C57Bl/6 J mice were used and directly acquired from Charles River. Under anesthesia with isoflurane (2-5 vol% for induction and 1, 5-2 Vol% for maintenance), supplemented with 1 L/min oxygen, PlGF KO and WT control mice or C57Bl/6 J mice of 8-12 weeks were subcutaneously implanted with 50 mg of DOCA pellet with a release time of 21 days (Innovative Research of America), as previously described. 18 Control groups of both genotypes received the appropriate placebo pellet (Innovative Research of America). Mice with DOCA were maintained with tap water plus 0.15 mol/L (0.9%) NaCl (DOCA-salt), whereas mice with placebo received tap water alone. All mice were then fed with standard chow diet ad libitum.
At the end of each experimental procedure, mice were euthanized by inhalation of an overdose of isoflurane.
Blood pressure measurements
Arterial BP was measured by tail cuff and radiotelemetry, accordingly to previously described procedures. 13, 18, 20 
Splenectomy and left coeliac ganglionectomy
C57Bl/6 J mice were anesthetized with isoflurane (2-5 vol% for induction and 1, 5-2 vol% for maintenance), supplemented with 1 L/min oxygen, to perform splenectomy or coeliac ganglionectomy (CGX) as previously described. 13 In brief, for splenectomy, the abdominal cavity of mice was opened and splenic vessels were cauterized, before careful removal of the spleen. Sham mice underwent the same surgical procedure to open the abdomen but without removing the spleen. After surgery mice were individually placed in thermal cages for a recovery period and then were implanted with DOCA-salt or placebo pellets.
For CGX execution, mice underwent a midline laparotomy and, after the isolation of both aorta and coeliac artery, the left coeliac ganglion was gently removed. In the group of sham mice, both aorta and left coeliac artery were isolated and then the left coeliac ganglion was exposed but without removing it. After surgery, mice were individually placed in thermal cages for the process of recovery, after which mice were implanted with DOCA-salt or placebo pellets.
The rate of mortality observed for both procedures ranged from 5% to 10% at maximum and was observable only during or immediately after surgery. In the post-operative period, mice were daily monitored to observe the eventual onset of adverse events, and if this was the case mice were killed.
Metabolic cages
During the last week of DOCA-salt or placebo protocol, PlGF KO and WT mice were individually housed in metabolic cages (Tecniplast), allowing acclimatization before starting with sampling of urine and plasma. Body weight was measured before and after metabolic cage entry. Mice had free access to tap water added with 0.9% NaCl for DOCA-salt group, whereas the placebo group of mice was maintained with tap water alone. Urine and plasma samples were used for assessment of analytes of interests with a clinical analyzer, accordingly to standard protocols.
Immunofluorescence and immunohistochemistry
For immunofluorescence analysis, the spleen was collected and embedded in optimal cutting temperature (OCT) compound. The following primary antibodies were used as previously described 13, 18 : rat anti-CD169 Quantitative analysis of white pulp area of the spleen was determined using Image J software (National Institute of Health (NIH)), as previously described. 18 For renal damage assessment, kidneys were explanted and embedded in paraffin for immunohistochemistry. Sections of 4 mm were deparaffinized and rehydrated before undergoing antigen retrieval. Slides were processed with the primary antibodies anti-CD8 (1:50; 550286, BD Pharmingen, CA, USA) and anti-CD4 (1:50; 550280, BD Pharmingen, CA, USA) and then incubated with biotinylated secondary antibodies (1:200; Vector laboratories, CA, USA) and processed with DAB (Vector laboratories, CA, USA). Hematoxylin (Sigma Aldrich, Missouri, USA) was used for nuclei counterstaining. The number of CD8 þ and CD4 þ cells per square micrometer was determined using the Image J software Cell Counter plugin analysis tool (NIH), as previously described. 13, 18 Analyses of renal damage were performed in tissue sections stained with Picrosirius Red, Masson's Trichrome, and periodic acid-Schiff (PAS). Images of kidney sections were used to calculate the size of renal corpuscle, glomerular area and Bowman's capsule, and the percentage of renal fibrosis, all using Image J software (NIH).
All images were captured using a DMI3000B Leica optical microscope provided by Leica Cameras (Leica Microsystems, Wetzlar, Germany) and processed with the Leica Application Suite (LAS V3.3).
Enzyme-Linked Immunosorbent Assay (ELISA) for determination of metabolites
PlGF protein levels were determined by a high sensitivity ELISA kit (R&D Systems, Minnesota, USA), as previously described. 13 Flash frozen splenic tissues were extracted with a buffer containing PBS and protease inhibitor cocktail (Sigma Aldrich, Missouri, USA). Results were expressed as picogram PlGF per milligram wet tissue. Noradrenaline (NA) levels were measured by a high sensitivity ELISA kit (IBL International, Hamburg, Germany), as previously described. 18 Flash frozen splenic and renal tissues were extracted with a buffer containing 0.1 N HCl and 1 mM EDTA. Results were expressed as nanomole NA per milligram wet tissue.
Flow cytometry
After mice were exsanguinated, both kidneys were collected. Cell suspensions were obtained by mechanically disrupting two decapsulated kidneys in 10 ml of RPMI 1640 medium (GIBCO, Invitrogen, CA, USA) supplemented with 5% FBS, which was then passed through a 70 lm sterile filter (Falcon, BD Biosciences, CA, USA). The resulting cell suspension was centrifuged at 300 g for 10 min to pellet the cells. To isolate leukocytes, the pellet was processed as previously described 13, 18 and lymphocytes were enriched from total cell suspension with Mouse T Lymphocyte Enrichment Set-DM (IMag BD Bioscience, CA, USA), and the number of the cells was assessed using trypan blue and an automated counter (Countess, Life Technologies, CA, USA). Cells were analyzed by flow cytometry staining with the following mix of antibodies: PerCPCy5.5 anti-CD8a (53-6.7) for identification of CD8 T cells, FITC anti-CD4 (RM4-5) for CD4 T cells, APC-Cy7 anti-CD45 (30-F11) for total leukocytes identification, APC anti-CD69 (H1.2F3), recognizing the early activation marker, and PE-Cy7 anti-CD44 (IM7) (1:100; BD Pharmingen, CA, USA) as an homing marker. Data were analyzed using FlowJo Software (V 10.0.8).
Statistical analysis
Sample size was pre-estimated on the basis of previously published research and from pilot experiments. Data distribution was assessed with D'Agostino Pearson test, and assumption of homogeneity of variance was tested using Levene's test of equality of variances. Statistical significance was assessed with the appropriate test according to each experimental design. In detail, multiple group analysis was performed with two-way analysis of variance followed by Bonferroni's post hoc and analysis for repeated measures was applied when required by the experimental setting. Data are presented as mean ± SEM. P < 0.05 was considered significant. Statistical analyses were performed with SPSS 23.0 (IBM Software) and graphs were made with GraphPad Software PRISM5.
Results
DOCA-salt hypertension recruits a sympathetic neural regulation of the spleen
The consolidated notion that hypertension induced by DOCA-salt challenge associates with T cells infiltration in the kidney, 8, 9 raised the interest in the search for molecular mechanisms regulating immune system upon this hypertensive hit. Despite immune mechanisms contributing to renal damage and BP regulation in DOCA-salt hypertension have been proposed, 21 we still ignore how lymphoid organs participate in the etiology of the disease. To gain information into this issue, we challenged splenectomized mice with DOCA-salt and measured BP. Mice deprived of the splenic immune system were unable to rise BP upon the saltsensitive hypertensive stimulus ( Figure 1A and B) , conversely to what is typically observed in control mice ( Figure 1A and B), thus suggesting a relevant role of splenic immune cells in DOCA-salt hypertension. We previously found that splenic nerve activity is sensitive to this hypertensive hit, as reflected by increased firing activity of the nerve early after DOCA-salt administration. 18 Here we found that DOCA-salt induces a precocious increase in the expression of tyrosine hydroxylase (TH), the rate-limiting enzyme of NA in the MZ of the spleen, defined by CD169 þ metallophilic macrophages ( Figure 1C and D) . ascertain the dependence of this sympathetic input on the nervous drive passing through the coeliac ganglion, we analyzed TH expression in a further group of mice where CGX was performed before DOCA-salt administration. DOCA-salt was unable to induce TH expression in mice subjected to CGX ( Figure 1C) , being the percentage of TH stained area in the spleen significantly reduced compared to sham mice subjected to the same challenge ( Figure 1D ). This result was further confirmed by the quantitative measurement of NA in the spleen, showing that DOCA-salt increased NA content and that CGX was effective in hampering its induction (see Supplementary material online, Figure S1A ). In order to assess the selectivity of this procedure in denervating the spleen without affecting the renal innervation, we also measured the NA content of contralateral kidney, which resulted unaffected (see Supplementary material online, Figure S1B ).
To add information on the functional relevance of this pathway, we monitored BP response to DOCA-salt challenge in a further group of CGX mice, as compared to the sham controls, finding that they were protected from hypertension ( Figure 1E and F) . 
PlGF is critically involved in DOCA-salt-induced hypertension
Previous studies showed that neural modulation of the spleen can have several effects in different pathophysiological contexts 13, 18, 22 and that the pathway activated by PlGF is crucial in immune functions involved in hypertensive responses to AngII. Thus, we sought to determine whether this pathway could be involved in mediating the response to DOCA-salt.
Immunofluorescence analysis showed that DOCA-salt administration significantly induced PlGF expression in the MZ of the WT spleen, marked by the co-staining with CD169 metallophilic macrophages (Figure 2A and B) and ERT-R7 fibroblast reticular cells (see Supplementary material online, Figure S2A) , as compared to the basal levels found in mice treated with placebo alone (Figure 2A and B) . As expected no signal of staining positive for PlGF was found in PlGF KO mice (Figure 2A and B) . To determine whether the activation of PlGF pathway was directly induced in the spleen or mediated by the increased sympathetic splenic drive activated by DOCA-salt, the percentageof PlGF positive area was also measured in mice subjected to CGX prior to starting the hypertensive challenge. As shown by immunofluorescence and related quantitative analysis, the sympathetic denervation of the spleen hampered PlGF expression upon DOCA-salt (Figure 2A and B) . In addition, we quantitatively measured PlGF protein levels, released in the spleen after DOCA-salt challenge, confirming the finding of a sympathetic-dependent release of PlGF upon DOCA-salt ( Figure 2C) . We next questioned whether this pathway had an impact on the hypertensive phenotype. Thus, we subjected PlGF KO mice and their WT controls to the 21 days protocol of DOCA-salt administration or placebo and chronically measured BP both by radiotelemetry and tail cuff. The results evidenced an indispensable role of PlGF to allow BP increase upon DOCA-salt challenge ( Figure 2D and E, see Supplementary material online, Figure S2B and C). As expected, placebo had no effect on BP of both genotypes ( Figure 2D and E, see Supplementary material online, Figure S2B and C).
Data obtained so far, proposed PlGF as a mediator of the neuroimmune drive recruited by DOCA-salt in the spleen. To rule out the possibility that this effect could be due to an impairment of PlGF KO in the activation of the sympathetic splenic drive, we assessed the effects of DOCA-salt on TH expression in the spleen. As shown by immunofluorescence and quantitative analysis of TH positive area in the MZ, there was no difference in the levels of up-regulation of SNS induced by DOCA-salt in PlGF KO mice as compared to WT controls (see Supplementary material online, Figure S3A and B), thus suggesting a local splenic effect of PIGF. Taken together, these results support the hypothesis that PlGF is the mediator of the cross-talk established between nervous and immune systems in DOCA-salt hypertension.
DOCA-salt-induced activation of co-stimulation process and deployment of T cells for consequent infiltration in target organs depends on PlGF
In order to investigate to which extent the activation of splenic PlGF mediated by DOCA-salt induced sympathetic splenic overdrive could affect the immune response involved in damage of target organs of hypertension, we assessed the amount of T cell deploying from the spleen. We performed immunofluorescence analysis to evaluate the area of CD3 þ T cells in the white pulp of the spleen, revealed by costaining with B220 labeled B cells. DOCA-salt induced a significant reduction of T cells in WT mice, whereas the spleens of PlGF KO mice remained unaffected, maintaining an equal amount of CD3 þ T cells as compared to placebo treated mice ( Figure 3A and B) . On this notice, it has been previously shown that DOCA-salt activates the process of T cells co-stimulation mediated by CD86, which is one of the main critical step in the full activation of T cells and prodromal for the later deployment from lymphoid organs. 8, 13, 18 ,23 Thus, we tested whether the neuroimmune modulation exerted by DOCA-salt in the spleen and mediated by PlGF was relevant for the activation of co-stimulation. To this aim, we analyzed the amount of CD86 positive staining, a typical pattern of activation expressed by APCs in the MZ and known to be regulated by DOCA. 8 Here we show that PlGF is indispensable to allow DOCA-salt induced co-stimulation on APC, being CD86 expression hampered in PlGF KO mice ( Figure 3C and D) . infiltration of activated immune cells in target organs, a crucial event contributing to BP increase and end-organ damage. 9, 13 Kidneys isolated from DOCA-salt treated mice were analyzed for determination of activated T cells content by flow cytometry. As shown by representative plots and quantitative analysis, WT mice subjected to DOCA-salt accumulated a significant amount of CD8 and CD4 T cells positive for markers of activation (CD69) and homing (CD44), as compared to placebo treated mice ( Figure 4A-F) .
Conversely, kidneys isolated from PlGF KO mice were spared from infiltrating activated CD8 and CD4 T cells, showing no significant difference when compared with placebo treated mice ( Figure 4A-F) . We further added evidence to this result by looking at immune cells infiltrating kidneys with immunohistochemistry (see Supplementary material online, Figure S4A-D) . Indeed, PlGF KO mice were protected from the significant increase of CD4 þ T and CD8 þ T cells observed in the renal tubules and glomeruli of WT mice challenged with DOCA-salt, as compared to mice receiving placebo alone (see Supplementary material online, Figure S4A -D).
PlGF KO mice are protected from DOCA-salt induced end-organ damage
To determine whether the protection from renal infiltration of activated immune cells, observed in PlGF KO upon DOCA-salt challenge resulted in protection from end-organ damage, we assessed renal fibrosis and glomerular injury. We found that upon DOCA-salt administration, WT mice showed a significant amount of renal fibrosis, evidenced by staining kidneys with Picrosirius Red and Masson's Trichrome ( Figure 5A-C) .
Instead PlGF KO mice were protected from renal fibrosis ( Figure 5A-C) , thus paralleling the observation that PlGF KO kidneys were spared from infiltrating activated T cells. The apposition of fibrotic tissue in WT mice treated with DOCA-salt was particularly evident in both glomeruli and tubules, thus suggesting that infiltrating T cells negatively affect the tissue homeostasis, determining in the long-term structural alterations that could deteriorate renal function, further contributing to the hypertensive phenotype. Accordingly, we also observed that chronic DOCA-salt challenge provoked an enlargement of renal corpuscle size and an increase of glomerular dimensions with an irregular area, as represented by PAS staining, which was otherwise absent in PlGF KO mice (Figure 5D and E; see Supplementary material online, Figure S5A ). The enlargement of Bowman's capsule size displayed by WT mice subjected to DOCAsalt was similarly reduced in PlGF KO mice (see Supplementary material online, Figure S5B ), thus further supporting that the inhibition of immune system activation and recruitment to target organs obtained in the absence of PlGF was effective in preventing not only BP increase but also end-organ damage. Finally, to provide functional data related to the above described renal injury, we assessed key parameters of renal function in PlGF KO and WT mice placed in metabolic cages at the end of DOCA-salt or placebo administration. A marked increase in urine output was observed after 21 days of DOCA-salt ( Figure 6A) , with a consequent reduction of urinary osmolality ( Figure 6B) . Despite the increase in urine output was significantly blunted in PlGF KO mice ( Figure 6A) , the urinary osmolality was comparable, as it was the plasma osmolality, moderately increased in both WT and PlGF KO mice ( Figure 6C) , thus suggesting that the stimulus induced by DOCA-salt determined an equal fluid balance in the two groups. When we measured renal function, the creatinine clearance was significantly reduced in WT mice but preserved in PlGF KO mice
( Figure 6D) . Similarly, PlGF KO mice were preserved from the DOCAsalt induced renal damage observed in WT mice, in terms of protein excretion, measured as total proteins to creatinine ratio. In fact, the marked increase observed in WT mice after 21 days of DOCA-salt was significantly hampered in PlGF KO mice ( Figure 6E ).
Discussion
The main findings of this study put in evidence that the activation of PlGF in the spleen is necessary to couple the brain-mediated effects of DOCA-salt challenge to the activation of immune cells directed toward kidneys, where they contribute to BP increase and organ damage. Summarizing our results (Figure 7) , we here show that (i) DOCAsalt challenge requires splenic immunity to drive hypertension; (ii) exploits the splenic sympathetic innervation to activate T cells through PlGF release in the MZ; and (iii) PlGF KO mice are protected from hypertension and target organ damage. Overall these data suggest that the brain-to-spleen neuroimmune circuit is a common pathway activated by different hypertensive hits, such as AngII 13 and DOCA-salt, to prime an immune response necessary to establish the hypertensive disease. ysis of CD4 and CD8 T cells, positive for the homing marker CD44 and for the early activation marker CD69, in PlGF KO and WT mice, treated with DOCA-salt or placebo. *P < 0.05, **P < 0.01 and ***P < 0.001 (n = 10 mice for PlGF WT placebo; n = 9 mice for PlGF KO placebo; n = 14 mice for PlGF WT and KO mice treated with DOCA-salt).
Placental growth factor, neuroimmunity, and deoxycorticosterone acetate-salt hypertension . DOCA-salt hypertension was not characterized by a generalized sympathoexcitation, 26 adding evidence to the notion that AngII and DOCAsalt hypertensive hits act in a completely different way in the periphery. However, this is not surprising as one of the main feature of the SNS is its highly heterogeneous regionality. Data presented in this work also evidence that the pathway mediating a neural modulation of immunity upon DOCA-salt hypertension, is not involved in the sensing of the stimulus, showing PlGF KO mice a similar pattern of fluid intake regulation. Whereas it becomes clear that the neuroimmune pathway mediated by splenic PlGF is downstream to sensing stations of DOCA-salt and primes immune cells lastly responsible for renal effects relevant for BP regulation and end-organ damage.
Overall, previous and present findings support the concept that a specific pattern of splanchnic SNS activity, required for the activation of immune system in the spleen, is commonly recruited by different hypertensive challenges, acting through distinct peripheral mechanisms of 
action. Hypertension is indeed a complex disorder that may arouse because of a wide variety of hits to BP homeostasis. 28, 29 Some of the mechanisms involved in regulation of BP levels are very different and various experimental models of hypertension have been developed in the attempt to recapitulate this complexity. DOCA-salt and chronic AngII are among the most used approaches to model different conditions observed in the human pathology. Despite the huge work that has been done to understand the different pathophysiological mechanisms underlying hypertension in these two conditions, it emerges now that their capability to commonly recruit the brain-to-spleen circuit, a primer of adaptive immunity, previously shown to crucially participate to the hypertensive disease characterized in both models. These findings further add a piece of knowledge in the understanding of how neuroimmune reflexes participate to the modulation of cell trafficking and lymphoid architecture in different pathophysiological contexts. 30 Notably, ablation of this neurosplenic axis has no effect in basal conditions, whereas it effectively protects from hypertension and its related target organ damage. The fact that the neurosplenic axis is dispensable in physiological conditions but essential in hypertension, sounds particularly important in terms of translational perspectives. A last opportunity from the clinical point of view is suggested by the availability of antibodies targeting PlGF already under investigation in advanced therapies for cancer and macular degeneration. [31] [32] [33] The insights here proposed, reporting the activation of a common neuroimmune mechanism underlying the hypertensive disease from different causes, strongly encourage the possibility to exploit a therapeutic strategy blocking this pathway, as a novel clinical opportunity for patients resistant to all ongoing available medications. On a different notice, our results also warrant another reflection relevant for the clinical implications emerging from the proof of concept that targeting PlGF mediated pathway would protect from hypertension. There is a consistent and increasing amount of reports in the literature that associates the use of anti-angiogenic therapies, mainly based on inhibitors of the VEGF (growth factor belonging to the same family of PlGF), with increased cardiovascular risk and, especially, induction of hypertension. 34 In principle, one would have expected that PlGF inhibition could have similar effects. (E) Protein excretion is expressed as the ratio between total urinary proteins and urinary creatinine in PlGF KO and WT mice, treated with DOCA-salt or placebo. *P < 0.05, **P < 0.01 and ***P < 0.001 (n = 5 mice for PlGF WT placebo, n = 6 for PlGF WT DOCA-salt and PlGF KO placebo, n = 7 for PlGF KO DOCA-salt).
Instead our previous 13 and present data demonstrate that it is not the case, being PlGF inhibition associated with a protection from BP increase and target organ damage in experimental models of hypertension. On this basis, data acquired so far would suggest that the inhibition of PlGF in cancer would have a dual positive role: on the one hand, it would protect from tumor growth [31] [32] [33] 35, 36 and at same time hamper hypertension. Future studies will be necessary to investigate this important translational perspective.
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